Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients - Wikidata - awgldk - TriplyDB

Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients

Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients

http://www.wikidata.org/entity/Q28072672

about

Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials.[Advances in the Treatment of Relapsed Small Cell Lung Cancer].

P2860

Q48125706-D4CA6496-9A89-4EDA-A1BD-F96DBA3BB745 Q53747313-C3B214EE-ED31-4A60-9F1E-A3DE5023F6D8

P2860

Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients

http://www.wikidata.org/entity/Q28072672

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

Amrubicin for relapsed small-c ...... meta-analysis of 803 patients

@ast

Amrubicin for relapsed small-c ...... meta-analysis of 803 patients

@en

Amrubicin for relapsed small-c ...... meta-analysis of 803 patients

@nl

type

label

Amrubicin for relapsed small-c ...... meta-analysis of 803 patients

@ast

Amrubicin for relapsed small-c ...... meta-analysis of 803 patients

@en

Amrubicin for relapsed small-c ...... meta-analysis of 803 patients

@nl

prefLabel

Amrubicin for relapsed small-c ...... meta-analysis of 803 patients

@ast

Amrubicin for relapsed small-c ...... meta-analysis of 803 patients

@en

Amrubicin for relapsed small-c ...... meta-analysis of 803 patients

@nl

P1433

Q28072672-1740759D-BCB7-4BAC-ABBB-CE05C256B0F2

P1476

Q28072672-2CC9C2CE-2B27-4400-9C48-77A3DEBF3662

P2093

Q28072672-0443AA1B-4E4C-4A9B-80CC-8B7EA4A89B6D

Q28072672-1BE73966-C8CE-4D16-8504-3F250851A4B6

Q28072672-1E8F660F-5F0B-4201-9F53-A57AC4FBBC5A

Q28072672-20AF8DF6-4D8F-4519-99B4-2CFB35AA2229

Q28072672-258A7268-5990-4EDE-8360-399AB65CE5F9

Q28072672-29C3722C-8AF2-4082-940E-E12F11248F35

Q28072672-2DE3524E-FEAE-471D-8BE7-E85BA590EE10

Q28072672-31321996-1E38-4C80-9ADC-3BF6A881A5EB

Q28072672-3A38BC71-B8FE-4F33-9909-EE794EAB5610

Q28072672-4E147392-7AC6-40CE-AB22-CA589E3005F6

P275

Q28072672-ABC2F243-B48C-4068-A87E-E956096C47B9

P2860

Q28072672-02D0DFD9-DB77-4A8F-8EEF-7F75B255132A

Q28072672-0B687231-7480-40F2-8B20-E800E9E3E12A

Q28072672-0D91EF82-CE11-43D7-89A9-3D2341435978

Q28072672-171DF658-D630-4E27-B220-DCE2A7477492

Q28072672-21CA1E4B-19C9-45FA-B5A3-5BE9060A4610

Q28072672-2AD99061-6684-49A7-B683-1EA7A43BEDC2

Q28072672-2BF6C0B3-84B7-488E-973D-6FDAC05E66DC

Q28072672-34DF296D-B723-4282-A492-72AEFF19C0C3

Q28072672-4B3781EE-3B3F-4076-9CAC-B8C82FE2799C

Q28072672-4F478F3B-257F-4795-85CB-B7FD397541E9

P2888

Q28072672-51F6F7B4-544C-4EDC-965E-B6DC8A937C94

P304

Q28072672-301F9F8A-CB67-40CD-914E-139E7AB73D61

P31

Q28072672-4654BDBE-0209-4503-8932-6FA6723EA144

Q28072672-7E8C172E-660D-4038-8FC4-985A871F6318

Q28072672-EB33EFA1-A8B4-4513-83F8-547BA4DD9997

P356

Q28072672-38AD01B7-2B13-4EB9-A570-C2F9F03E2DA5

P407

Q28072672-D52625AC-A5A5-4996-BCD5-F5EC20B10F2F

P478

Q28072672-3E4C4070-93D1-4FF6-9C1A-5D271ABE2E95

P50

Q28072672-C83033FB-2BD5-4992-8966-4AB41A46C9D5

P5008

Q28072672-D60A0E7B-EC47-4CF1-AF06-51FD17C29AA3

P577

Q28072672-C2698DB3-B3BE-417C-B207-9235FB41AAC6

P6179

Q28072672-8A073EED-8D65-4918-AFDA-641A6489DEDA

P698

Q28072672-0C002F9F-2DC2-4976-A3C2-BC2FEAE3BB91

P921

Q28072672-2A2CADD2-0853-4A35-BDB5-461DCBD4B712

Q28072672-2C5BC99D-9AD9-4659-9AC8-AD3E05D304CD

Q28072672-7B788039-A5E0-412D-B929-BF409791F682

Q28072672-B6059A96-72C1-434C-9BB8-CADF655BD835

Q28072672-C2D8FCE8-02E9-43F3-B4E1-4061B3CD7EB1

Q28072672-D54952C5-6884-4DB0-B933-508F0DA5FD4C

Q28072672-DCE82FE1-AECC-4BC4-BE5C-5401E122E543

P932

Q28072672-226CC7D9-3D0D-42BB-AD85-B6DA0BD605ED

P356

P1433

Scientific Reports

P1476

Amrubicin for relapsed small-c ...... meta-analysis of 803 patients

@en

P2093

Hideyuki Nagakura

http://www.w3.org/2001/XMLSchema#string

Hiroki Watanabe

http://www.w3.org/2001/XMLSchema#string

Ken Tashiro

http://www.w3.org/2001/XMLSchema#string

Kenjiro Nagai

http://www.w3.org/2001/XMLSchema#string

Kentaro Nakashima

http://www.w3.org/2001/XMLSchema#string

Makoto Kudo

http://www.w3.org/2001/XMLSchema#string

Masaharu Shinkai

http://www.w3.org/2001/XMLSchema#string

Masaki Yamamoto

http://www.w3.org/2001/XMLSchema#string

Misako Ikeda

http://www.w3.org/2001/XMLSchema#string

Nobuaki Kobayashi

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Measuring inconsistency in meta-analyses

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

How should meta-regression analyses be undertaken and interpreted?

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.

Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

P2888

P304

18999

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P356

10.1038/SREP18999

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2016-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1015229641

http://www.w3.org/2001/XMLSchema#string

P698

26750506

http://www.w3.org/2001/XMLSchema#string

P921

Angliavandeniai

lung small cell carcinoma

heterocyclic compound

polycyclic compound

P932

4707435

http://www.w3.org/2001/XMLSchema#string